doi:https://doi.org/

References:

Botto F., Alonso-Coello P., Chan M.T., et al. Myocardial injury after noncardiac surge ry: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014; 120:564—578.
Devereaux P.J., Biccard B.M., Sigamani A., et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017; 317:1642—1651.
Puelacher C., Lurati Buse G., Seeberger D., et al. Perioperative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. Circulation 2018;137:1221—1232.
Devereaux P.J., Xavier D., Pogue J., et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523—528.
Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020—2035.
Levy M., Heels-Ansdell D., Hiralal R., et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology 2011;114:796—806.
Devereaux P.J., Sessler D.I. Cardiac complications and major noncardiac surgery. N Engl J Med 2016;374:1394—1395.
Eikelboom J.W., Anand S.S., Malmberg K., et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936—4192.
Andreotti F., Testa L., Biondi-Zoccai G.G., Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006;27:519—526.
Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9—19.
Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319—1330.
Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949—956.
Eriksson B.I., Dahl O.E., Huo M.H., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721—729.
Duceppe E., Parlow J., MacDonald P., et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol 2017;33:17—32.
Foucrier A., Rodseth R., Aissaoui M., et al. The long-term impact of early cardiovascular therapy intensification for postoperative troponin elevation after major vascular surgery. Anesth Analg 2014;119:1053—1063.
Oldgren J., Budaj A., Granger C.B., et al. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781—2789.
Altman D.G., Bland J.M. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.